Endothelial cells are critically involved in the pathogenesis of inflammation, which is characterized by vasopermeability, plasma leakage, leukocyte recruitment, and neovascularization. Therefore, inhibitors of endothelial cell function could reduce inflammation. In this study, we evaluated the effects of the angiogenesis inhibitor vasostatin on inflammations induced by contact hypersensitivity reactions in mouse ears. Vasostatintreated mice revealed significantly reduced edema formation, resulting from lower plasma leakage and inhibition of inflammation-associated vascular remodeling. Intravital microscopy studies of inflamed ears showed a decrease in the fraction of rolling leukocytes in vasostatin-treated mice, and Lycopersicon esculentum lectin-perfused ears revealed fewer leukocytes adherent to the vessel wall. The inflammatory infiltrate from vasostatin-treated mice was characterized by fewer CD8 þ T cells, neutrophils, and macrophages compared to the saline-treated animals. In a modified Miles assay, vasostatin inhibited vascular endothelial growth factor-Ainduced permeability, and inflamed ear tissues from vasostatin-treated mice expressed significantly reduced levels of the vascular destabilizer angiopoietin-2. These results reveal a previously unrecognized antiinflammatory property of the angiogenesis inhibitor vasostatin, and suggest that vasostatin is a potential candidate drug for the treatment of inflammation.
INTRODUCTION
The vascular endothelium is an important component of the inflammatory response and manifests striking changes during inflammation. As a result, vascular hyperpermeability, tissue edema, and perivascular inflammatory infiltrate characterize inflamed tissues. Moreover, endothelial cells are an important source of proinflammatory and proangiogenic factors. Therefore, the increased vascular surface area resulting from inflammation-associated angiogenesis is an important component of inflammations, as it translates to an extended capacity for cytokine production, adhesion molecule expression, and leukocyte recruitment (Jackson et al., 1997) . In fact, there is accumulating experimental evidence that angiogenesis and inflammation are closely interlinked (Braverman and Sibley, 1982; Jackson et al., 1997; Lange-Asschenfeldt et al., 2002; Oura et al., 2002; Kunstfeld et al., 2004) .
The experimental contact hypersensitivity (CHS) reaction is a model for an acute inflammatory response that is accompanied by a robust increase in the index of proliferating endothelial cells (Polverini et al., 1977) . This model has been utilized to demonstrate that angiogenesis factors modulate inflammation. For instance, mice that overexpress the proangiogenic factors, vascular endothelial growth factor-A (VEGF-A) (Kunstfeld et al., 2004) or placental growth factor (Oura et al., 2002) , react with an exaggerated ear swelling response associated with increased edema formation and vascular remodeling. In contrast, the CHS response in placental growth factor-deficient mice is much less pronounced (Oura et al., 2002) . Meanwhile, mice that lack the angioinhibitor thrombospondin-2 exhibited a prolonged and persistent inflammation accompanied by enlarged vessels (Lange-Asschenfeldt et al., 2002) . The positive correlation between enhanced vascularity and increased inflammatory responses and the abundance of factors that modulate angiogenesis known to be upmodulated during inflammatory responses (Detmar et al., 1994; Brown et al., 1995; Dvorak et al., 1995; Schroder and Mochizuki, 1999; Kuroda et al., 2001; Oura et al., 2002; Scott et al., 2002) confirm that the endothelium is active and relevant in the pathophysiology of inflammatory diseases.
However, studies addressing the physiological role of angiogenesis inhibitors during inflammation and potential therapeutic approaches with these factors in inflammation remain scant. In the past years, it has been demonstrated that blocking VEGF-A signaling resulted in suppressed edema formation in experimental inflammations. Furthermore, following treatment with the angiogenesis inhibitors TNP-470, caplostatin, and angiostatin, vascular leakage was reduced in experimental inflammations. In this study, we assessed the effect of a treatment regimen with the naturally occurring angiogenesis inhibitor vasostatin (Pike et al., 1998 (Pike et al., , 1999 in an experimental CHS reaction in mice sensitized against oxazolone.
Vasostatin, an endothelial cell inhibitory factor originally isolated in culture supernatants of Epstein-Barr virus-immortalized cells, consists of the amino-terminal domain of calreticulin inclusive of residues 1-180. Vasostatin inhibits the proliferation of endothelial cells stimulated with basic fibroblast growth factor and VEGF-A and suppresses neovascularization and tumor growth in vivo. (Pike et al., 1998 (Pike et al., , 1999 . Here, we report that systemic treatment with recombinant vasostatin resulted in a diminished inflammatory response in the ear skin of mice. We observed reduced edema formation, leukocyte recruitment, and vascular remodeling following vasostatin treatment. Moreover, vasostatin potently inhibited VEGF-A-induced permeability in vivo and inhibited the upregulation of the vascular destabilizer angiopoietin (Ang)-2 observed in the inflamed lesions. Our study reveals a novel function for the angiogenesis inhibitor vasostatin as an anti-inflammatory substance, suggesting that therapeutic strategies using vasostatin and other angiogenesis antagonists could represent a novel approach for the treatment of inflammations.
RESULTS

Vasostatin reduced experimentally induced cutaneous inflammation and vascular leakage
Mice sensitized to oxazolone by topical application on the abdomen and paws were challenged with topical application of oxazolone to the right ear. The left ear was treated with vehicle alone. Before oxalozone challenge, mice were treated intraperitoneally with vasostatin (130 mg/mouse; 24 and 2 hours before challenge) and treatment continued every 24 hours in the post-challenge period. Twenty-four and 48 hours after the onset of a CHS, we observed 38 and 31% (Po0.001) less edema, respectively, in the vasostatin-treated compared to the saline-treated mice in the mouse ear swelling test (Figure 1a ). This effect of vasostatin was observed throughout the recovery period of 7 days: 72 hours postchallenge and thereafter, we observed 50% less edema in the vasostatin-treated ears compared to the saline-treated skin.
To quantify the observed diminished edema formation in the inflamed skin of vasostatin-treated mice, we performed Evans blue leakage assays. Twenty-four hours after the induction of the CHS, we observed 43% less plasma extravasation of Evans blue dye (EBD) into the inflamed skin of vasostatin-treated compared to the saline-treated mice (243.4728.4 ng EBD/mg tissue, saline-treated; 138.4724.0 ng EBD/mg tissue, vasostatin-treated; Po0.05) (Figure 1b ). Histological analysis of the inflamed murine ear skins 24 and 48 hours after the onset of CHS confirmed decreased edema formation following vasostatin treatment (Figure 1c) . The morphology of blood vessels in the inflamed skin of vasostatin-and saline-treated mice was studied using transmission electron microscopy. In saline-treated mice, more endothelial cells developed a thin, irregular membrane and contained inter-endothelial gaps and fenestrations (Figure 2 , left panel). In the vasostatin-treated mice, interendothelial junctions appeared tight and fewer gaps were observed (Figure 2 , right panel).
Vasostatin reduced VEGF-A-induced vascular leakage
As VEGF-A is known to play a key role in enhancing vascular leakage (Senger et al., 1983; Thurston et al., 1999) and (a) Mouse ear swelling test of vasostatin-and saline-treated mice after the induction of CHS reactions. Ear swelling is expressed as the increase (change) over the original ear thickness in mm. At least nine saline-and nine vasostatintreated mice were analyzed per time point (data are representative of three independent experiments). (b) Twenty-four hours after the induction of an CHS reaction, mice were injected intravenously with EBD and subsequently perfused to clear the vessels of circulating dye. The EBD that leaked into the surrounding tissue was extracted, and the level of protein-bound dye per mg of tissue was quantified as a measure of vascular leakage. At least six saline-and six vasostatin-treated mice were analyzed per time point (data are representative of two independent experiments). (c) Thin sections (2 mm) of inflamed skins of saline-and vasostatin-treated mice 24 and 48 hours after the induction of CHS reactions. Data are expressed as mean7SEM. *Po0.05, **Po0.01 and ***Po0.001. The two-sided unpaired Student's t-test was used for statistical analyses. Bar ¼ 100 mm.
inflammation (Brown et al., 1995; Kunstfeld et al., 2004) , we investigated whether vasostatin controls plasma extravasation directly by inhibiting VEGF-A-induced vascular permeability. For this purpose, we quantified the extravasated EBD in response to intradermally injected VEGF-A in the skin using a modified Miles assay. Vasostatin diminished VEGF-A-induced vascular hyperpermeability in the skin of mice by 37% (12.771.8 mg EBD, saline-treated; 8.070.4 mg EBD, vasostatin-treated; Po0.05), whereas there was no difference in the leakage induced by intradermal injections of saline (3.270.5 mg EBD, saline-treated; 1.970.5 mg EBD, vasostatintreated) (Figure 3 ).
Vasostatin decreased the vascularity in the inflamed skin of mice
Forty-eight hours following the onset of an inflammation, we observed fewer blood vessels in the inflamed ears of vasostatin-treated mice when compared to saline-treated mice ( Figure 4a ). Computer-assisted morphometric image analyses of the panendothelial cell marker CD31-immunostained blood vessels revealed a significant decrease in the number of vessels per mm ear length in the vasostatin-treated compared to the saline-treated inflamed skins (50.871.4 blood vessels (BV)/mm, saline-treated; 43.273.1 BV/mm, vasostatin-treated; www.jidonline.org
Po0.05) (Figure 4b ). We then performed vessel size distribution analysis, where we compared the total number of vessels grouped according to the size of the vessels. This analysis revealed significantly fewer vessels (27%), with average vessel size ranging in size between 500 and 2,000 mm 2 (9.870.9 BV/ mm, saline-treated; 7.170.2 BV/mm, vasostatin-treated; Po0.05) (Figure 4c ). The vessels that fall into this size range are arterioles and post-capillary venules. As CD31 also positively stains lymphatic endothelial cells, we could not exclude a vasostatin-mediated effect on the lymphatic vasculature. However, we observed no difference in the average size, density, or size distribution of lymphatic vessels as judged by LYVE-1-stained sections between the groups (data not shown), confirming that vasostatin inhibited blood vascular remodeling during CHS.
Vasostatin diminished the inflammatory infiltrate in the inflamed skin
The infiltrating cells in the inflamed skin of vasostatin-and saline-treated mice consisted mainly of neutrophil granulocytes, macrophages, and lymphocytes. Analysis of the inflammatory infiltrate using tissue sections immunostained with antibodies directed against Ly6-G, to identify neutrophil granulocytes revealed a significant decrease in the number of neutrophils in vasostatin-treated mice compared to salinetreated mice at 24 hours ( and CD4 þ T cells in the uninflamed skin of saline-and vasostatin-treated mice.
Vasostatin diminished leukocyte-endothelium interaction in inflamed skin
As the proangiogenic factor VEGF-A and the antiangiogenic factor thrombospondin-2 (LangeAsschenfeldt et al., 2002) have been shown to influence the leukocyte-endothelial interaction, we performed intravital microscopy of blood vessels in uninflamed and inflamed skin of mice treated with vasostatin or saline. The edema in the inflamed ears of the mice in both groups made it difficult to obtain reliable measurements at 24 hours post-challenge. We therefore selected a time point of 6 hours following antigen challenge, as our previous experiments indicated changes in leukocyte adhesion as early as 2 hours following the onset of inflammation, while maintaining optimal visualization of the leukocytes in vivo. After injection of Rhodamine-6G, intravital microscopy revealed no difference in the baselinerolling fraction in the uninflamed skin of the vasostatin-and saline-treated mice. However, the rolling fraction of leukocytes in the inflamed cutaneous blood vessels of vasostatintreated mice was decreased by 40% when compared to the inflamed skin of saline-treated mice (4675%, vasostatintreated and 6973%, saline-treated; Po0.01) (Figure 6a ). In addition, whole mounts of inflamed ear skin after vascular perfusion with the lectin Lycopersicon esculentum, which binds to N-acetyl-D-glucosamine residues on the luminal surface of vascular endothelial cells and to leukocytes (Thurston et al., 1996) , revealed decreased inflammatory cells adherent to the endothelium of the blood vessels in the vasostatin-treated compared to the saline-treated mice 24 hours following antigen challenge (Figure 6b ), confirming the data obtained from the intravital studies. We therefore tested whether vasostatin directly influenced the expression level of intercellular adhesion molecule, vascular cell adhesion molecule, E-selectin, and VE-cadherin on the surface of tumor necrosis factor-a-stimulated human dermal microvascular endothelial cells in vitro using FACS analyses. Although the stimulated human dermal microvascular endothelial cells had increased levels of the tested cell adhesion molecules, vasostatin at 10 or 100 mg/ml had no significant effect on the cell-surface expression of the tested cell adhesion molecules.
Vasostatin blocked the upregulation of Ang-2 in the inflamed ear skin VEGF-A (Senger et al., 1983; Thurston et al., 1999 ) is a potent inducer of vascular hyperpermeability, whereas Ang-1 has been shown to inhibit vascular leakage (Thurston et al., 1999 Gamble et al., 2000) . Therefore, we analyzed the expression pattern of these factors as well as the Ang-1 antagonist Ang-2 using quantitative real-time reverse transcription-PCR (RT-PCR). We found no difference in the expression pattern of VEGF-A or Ang-1 mRNA between the vasostatin-and saline-treated mice (Figure 7) . However, we found a more than 2-fold increase in the relative transcript level of Ang-2 mRNA in the inflamed skin of saline-treated mice when compared to the vasostatin-treated mice (1.970.08, vasostatin-treated and 5.770.02, saline-treated; Po0.001). There was no difference in the relative transcript level of Ang-2 mRNA expression in the uninflamed skin of either group (2.470.28, vasostatin-treated and 1.970.08, (a) Six hours after the induction of CHS reactions, Rhodamine-6G was intravenously administered to visualize leukocytes in vivo using intravital microscopy. The rolling fraction of leukocytes in postcapillary venules in the skin of vasostatin-and saline-treated mice was determined. At least four saline-and four vasostatin-treated mice were used for the experiments. (b) Twenty-four hours after the onset of the inflammation, vasostatin-and saline-treated mice were perfused with L. esculentum lectin and whole mounts of the ears were used to visualize leukocytes adherent to the wall of blood vessels (arrowheads). Four saline-treated and four vasostatin-treated mice were used in the experiment. Data are expressed as mean7SEM. **Po0.01. The two-sided unpaired Student's t-test was used for statistical analyses. Bar ¼ 25 mm. The mRNA expression of VEGF-A, Ang-1, and Ang-2 was measured in the skin of saline-treated and vasostatin-treated mice 24 hours after the onset of CHS reactions using real-time RT-PCR analyses. Four saline-and four vasostatin-treated mice were used for the experiment. Data are expressed as mean7SEM. ***Po0.001. The two-sided unpaired Student's t-test was used for statistical analyses.
www.jidonline.orgsaline-treated) ( Figure 6 ). Interestingly, elicitation of CHS resulted in a 2-fold increase of Ang-2 mRNA expression in saline-but not in vasostatin-treated mice.
DISCUSSION
Vasostatin treatment during experimental cutaneous CHS responses resulted in a striking anti-inflammatory effect evidenced by suppressed vasopermeability, edema formation, inflammatory cell influx, and angiogenesis. To our knowledge, this is the first description of an angiogenesis inhibitor with broad-range anti-inflammatory action. Previous reports have demonstrated suppressed edema formation during CHS reactions following the functional blockage of the proangiogenic factor VEGF-A (Kunstfeld et al., 2004) and reduced vascular leakage in CHS reactions in the presence of the angiogenesis inhibitor TNP-470, caplostatin, and angiostatin (Satchi-Fainaro et al., 2005) . Vascular integrity is fundamental in maintaining a physical barrier between blood components and the underlying tissue. During inflammation, plasma leakage is thought to occur primarily through intercellular gaps that form between endothelial cells or through the vesiculovacuolar organelle. Plasma components are able to cross from the lumen into the basement membrane through intercellular gaps or through the direct transendothelial channel created by the vesiculovacuolar organelles at sites of augmented vascular permeability (Thurston et al., 1996; Dvorak and Feng, 2001) . Transmission electron microscopy studies of the inflamed ears of vasostatin-treated mice revealed morphological features associated with reduced vascular hyperpermeability. Dermal capillaries and venules in the inflamed ear skin of vasostatin-treated mice contained fewer gaps and the interendothelial junctions in the vessels appeared tight compared to the inflamed skin of saline-treated mice (Figure 2) , as revealed by transmission electron microscopy.
In our hands, vasostatin suppressed VEGF-A-induced hyperpermeability in vivo as revealed by using a modified Miles assay, but did not influence the expression of VEGF-A in inflamed tissue as shown by real-time RT-PCR analyses. However, vasostatin completely blocked the upregulation of Ang-2 mRNA in vivo during the inflammation and this observation could, at least in part, explain the increased vascular integrity in the inflamed tissue following vasostatin treatment. Ang-2 is a vascular destabilizer that, similar to VEGF-A, has been shown to disrupt endothelial adherens junctions, thereby contributing to inter-endothelial gap formation (Carter, 2001) and is believed to be involved in the formation of intercellular openings in tumor vessels, leading to their leaky nature (Hashizume et al., 2000) . Moreover, Ang-2 is potently upregulated in the synovial tissue in rheumatoid arthritis (Scott et al., 2002) and in psoriatic lesions (Kuroda et al., 2001) , highlighting an important role of Ang-2 in inflammatory diseases. In contrast, the vascular stabilizer Ang-1 has been demonstrated to play a crucial role in controlling vascular leakage. For example, mice with targeted epidermal overexpression of Ang-1 were resistant to leakage induced by histamine, serotonin, and mustard oil (Thurston et al., 1999) , and adenoviral injection of Ang-1 resulted in the inhibition of plasma leakage normally induced by VEGF-A and mustard oil . Moreover, co-overexpression of Ang-1 with VEGF-A reversed the enhanced baseline leakage seen in the transgenic mice that overexpressed VEGF-A alone (Thurston et al., 1999) . Importantly, Ang-2 is a competitive antagonist to Ang-1. Therefore, vasostatin could protect the interaction between Ang-1 on vascular supporting cells and Tie-2 on endothelial cells, promoting vascular quiescence and protecting against plasma leakage.
In agreement with its known activity as an angiogenesis antagonist, vasostatin treatment resulted in reduced inflammation-associated vascular remodeling. Size distribution analyses revealed a decrease in the frequency of vessels ranging in size between 500 and 2,000 mm 2 . In the skin, the majority of vessels in this size range are post-capillary venules (Braverman, 2000) and our data indicate that vasostatin treatment resulted in fewer enlarged post-capillary venules. This observation is in agreement with increasing evidence, suggesting that inflammation-associated angiogenesis consists predominantly of the enlargement of existing vessels as opposed to the growth of new capillaries (Braverman and Sibley, 1982; Lange-Asschenfeldt et al., 2002; Oura et al., 2002; Kunstfeld et al., 2004) .
Remodeled venules are not only sites of focal plasma leakage but also of extensive inflammatory cell recruitment. The infiltration of leukocytes into inflamed tissues requires a chain of molecular events that mediate the rolling, adhesion, and extravasation of these cells in post-capillary venules (Springer, 1994; Butcher and Picker, 1996) . Using intravital microscopy, we found that the fraction of rolling leukocytes in the inflamed skin of vasostatin-treated mice was significantly decreased when compared to saline-treated mice, although no difference was observed in the uninflamed skin of the two groups. Concomitantly, we observed fewer neutrophils, macrophages, and CD8 þ T cells infiltrating the inflamed skin following vasostatin treatment. This contributed to the attenuated inflammation as these inflammatory cells are important sources of cytokines, chemokines, and growth factors that promote and perpetuate the inflammatory response.
The connection between angiogenesis inhibitors and the leukocyte-endothelial cell interaction is only beginning to be appreciated. Transgenic VEGF-A overexpression led to enhanced rolling of leukocytes in cutaneous post-capillary venules, and this effect was obliterated following systemic treatment with antibodies directed against P-and E-selectin . Likewise, mice that lack the endogenous angiogenesis inhibitor thrombospondin-2 are characterized by enhanced leukocyte rolling and an increased number of P-selectin-positive blood vessels (Lange-Asschenfeldt et al., 2002) . Recently, the endogenous angiogenesis inhibitor angiostatin was found to inhibit the recruitment and adhesion of neutrophils and macrophages to the endothelium and their transmigration in vitro (Chavakis et al., 2005) . In accordance, vasostatin-treated mice showed reduced leukocyte-endothelial cell interaction and diminished recruitment and transmigration of inflammatory cells into inflamed tissue. However, we found no significant change in the expression level of several cell adhesion molecules on the surface of tumor necrosis factor-astimulated endothelial cells following vasostatin treatment. Yet, the regulation of cell adhesion molecules by vasostatin cannot be ruled out as leukocyte recruitment is not restricted to the tested molecules. In fact, the Angs have been shown to induce the expression of platelet-activating factor and the b2-integrin complex on neutrophils, all of which are involved in the adhesion of these cells to the endothelium (Lemieux et al., 2005) . As vasostatin inhibited inflammation-associated Ang-2 upregulation, this could provide a mechanism by which vasostatin suppressed the rolling fraction of leukocytes and the number of neutrophils infiltrating the inflamed skin.
Angiogenesis, whether vascular remodeling or neovascularization, is an important component of inflammatory diseases like rheumatoid arthritis and psoriasis. In rheumatoid arthritis, the newly sprouted vasculature supports the development of pathological tissue that invades the healthy tissue and destroys the joints. Moreover, vascular hyperpermeability resulting in gross tissue edema is a hallmark of many diseases like contact dermatitis and uticaria. Current therapeutic options are mainly restricted to immunosuppressive therapies using corticosteroid treatment or application of other immunosuppressive agents (topical and systemic). These treatment regimens are associated with substantial side effects including super-infection and atrophy of the skin, and long-term use can result in the development of malignant lesions.
Our results strongly suggest that the development of treatment options using angiogenesis inhibitors might benefit inflammatory diseases because of the observed suppression of vascular leakage, leukocyte recruitment, and angiogenesis following vasostatin treatment. Vasostatin is small, soluble, and easy to produce. The recombinant protein seems to be stable for more than 9 months in aqueous solutions, and the effective dose of vasostatin (Pike et al., 1998) is much lower than other angiogenesis inhibitors making vasostatin an attractive therapeutic candidate. Additional studies are necessary to evaluate the long-term effects of vasostatin treatment, the possibility of topical application of vasostatin, and whether it would benefit chronic inflammatory conditions.
MATERIALS AND METHODS Animals
Eight-to 10-week-old female friends virus B mice (Charles River Wiga GmbH, Sulzfeld, Germany) were used for experiments. Mice were anesthetized with a mixture of ketamine (800 mg/10 g body weight ketamine; Sigma-Aldrich, Taufkirchen, Germany) and avertin (0.5 mg/10 g body weight 2,2,2,-tribromoethanol in 2.5% Rtamyl alcohol; Sigma-Aldrich) as described (Lange-Asschenfeldt et al., 2002) , and the government of the state of Schleswig-Holstein, Germany, approved all animal procedures.
Induction of CHS reactions in mice
CHS reactions were induced in the ear skin of 8-to 10-week-old female friends virus B mice as described previously (Galli and Hammel, 1984; Lange-Asschenfeldt et al., 2002) . Mice were sensitized by topical application of a 2% oxazolone (4-ethoxymethylene-2-phenyl-2-oxazoline-5-one; Sigma-Aldrich) solution in acetone/olive oil (4:1 (vol/vol)) to the shaved abdomen (50 ml) and to each paw (5 ml). Five days after sensitization, the right ears were challenged by topical application of 20 ml of a 1% oxazolone solution, whereas the left ears were treated with the vehicle alone. The thickness of vehicle-and oxazolone-treated ears (at least six animals per time point) was measured using a dial thickness gage (Mitutoyo, Japan) as described (Lange-Asschenfeldt et al., 2002) . The increase in ear thickness over the baseline levels, defined as the thickness before the induction of the inflammation, was used as a parameter for the extent of inflammation (Gad et al., 1986) . Data are expressed as mean7SE of the mean. The two-sided unpaired Student's t-test was used for statistical analyses.
Vasostatin treatment
Eight-to 10-week-old mice received intraperitoneal injection of either 200 ml of 0.9% saline or were treated with the same volume saline containing 130 mg of vasostatin (5.2 mg/kg body weight) 24 and 2 hours before challenge and every 24 hours during the postchallenge period. Recombinant vasostatin was produced as described (Pike et al., 1998) . The purified protein was tested for endotoxin by the Limulus Amebocyte Lysate kinetic-QCL assay and was found to contain less than 5 endotoxin units/10 mg protein.
Evans blue permeability assay and modified Miles assay
Twenty-four hours after challenge, EBD (100 ml of a 1% solution in 0.9% NaCl; Sigma-Aldrich) was injected into the retro-orbital plexus of anesthetized vasostatin-and saline-treated friends virus B mice. Fifteen minutes after the injection, mice were perfused as described (Thurston et al., 1999) . Ears were removed, dried, weighed, and incubated in 1 ml formamide (Sigma-Aldrich) at room temperature for 5 days to extract the Evans blue from the tissue. Dye concentration was measured at 620 nm using a spectrophotometer and the value obtained was reported as ng/mg of ear tissue. For the modified Miles assay, 24 hours after challenge, EBD was injected into the retro-orbital plexus of anesthetized vasostatin-and salinetreated friends virus B mice. After 10 minutes, 50 ml of 0.9% NaCl alone and human VEGF165 (200 ng in 50 ml of saline; Peprotech, London, UK) was injected intradermally into the back skin as described previously (Miles and Miles, 1952; Claffey et al., 1996; Oura et al., 2002) . After 30 minutes, the area of skin that included the blue spot resulting from leakage of the dye was removed. EBD was extracted from the skin by incubation with formamide for 5 days at room temperature, and the absorbance of extracted dye was measured at 620 nm using a spectrophotometer (Thurston et al., 1999) . Data are expressed as mean7SEM. The two-sided unpaired Student's t-test was used for statistical analyses.
L. esculentum lectin perfusions
Vascular perfusions were performed as described previously (Thurston et al., 1996) . Briefly, 24 hours after the onset of an inflammation, 8-week-old vasostatin-or saline-treated mice were anesthetized as described above, and 200 ml (1 mg/ml) of biotinylated L. esculentum lectin (Vector Laboratories, Burlingame, CA) was injected into the retro-orbital venous plexus. After this intravenous injection, the animals were perfused via the left ventricle with fixative (1% paraformaldehyde and 0.5% glutaraldehyde in phosphate-buffered saline (PBS), pH 7.4) followed by perfusion with PBS.
Ears were removed, stained using the Vectastain Elite ABC kit (Vector Laboratories), and examined by light microscopy.
Histology and immunohistochemistry
Mice were killed 24 and 48 hours after oxazolone challenge. Ears were embedded in optimal cutting temperature compound (Sakura Finetek Europe BV, Zoeterwoude, The Netherlands) and were frozen on liquid nitrogen. Hematoxylin/eosin stains were performed following standard protocols. Immunohistochemical stains were performed on 10 mm cryostat sections as described (Streit et al., 2000) , using monoclonal rat antibodies against CD31 (clone MEC 13.3), Ly6-G (clone RB6-8C5), CD4 (clone H129.19), CD8 (clone 53-6.7), (all from BD Biosciences Pharmingen, Erembodem, Belgium) or against F4/80 (clone CI: A3-1; Caltag Laboratories GmbH, Hamburg, Germany), with the corresponding biotinylated secondary antibody and the horseradish-peroxidase-conjugated Vectastain Elite ABC kit (Vector Laboratories).
Transmission electron microscopy
Twenty-four and 48 hours after oxazolone challenge, ears of vasostatin-and saline-treated mice were processed for electron microscopy in a standard manner (Eady, 1985) . Ears were subjected to Karnovsky's fixative that was then substituted by cacodylate buffer. Specimens were post-fixed in 1.3% osmium tetroxide in distilled water. Subsequent staining was performed with 2% uranyl acetate in 50% ethanol. After dehydration in a graded alcohol series, ethanol was substituted by propylene oxide and the ears were embedded in Epon (Agar Scientific Ltd, Stansted, UK). Ultrathin sections were double-stained with uranyl-acetate and lead citrate. For microscopy and photographs, a Zeiss electron microscope (EM S 10; Leo, Oberkochen, Germany) was used.
Computer-assisted morphometric vessel analyses CD31-labeled sections (at least six per time point) were examined using an Axiotech 100 Upright Microscope (Zeiss, Gena, Germany), and images were captured with a PowerShot G2 digital camera (Canon Deutschland GmbH, Krefeld, Germany) . Morphometric analyses of digital images were performed using the IP-LAB software (Scanalytics Inc., Fairfax, VA). At least three individual fields per section were examined at original magnification Â 100, and the number of vessels per mm ear length (Kunstfeld et al., 2004) and the size of vessels were measured as described previously (Streit et al., 1999) . The determination of vessel density, that is, the number of vessels per tissue area unit, has been frequently used to characterize tumor and wound angiogenesis (Streit et al., 1999) . However, the marked increase of tissue area in inflamed mouse skin, resulting from increased vascular leakage and edema formation, prevented a meaningful analysis of vessel densities in our study. For this reason, a modified method has been used to analyze vascularity in inflamed murine skin, where the total number of vessels per mm of ear length between the groups is compared (Kunstfeld et al., 2004) . In order to determine which type of vessels were mainly affected in response to vasostatin treatment, we performed size distribution analyses. In these analyses, we grouped the total number of vessels according to their size. Capillaries are represented by the vessel population with a size under 100 mm 2 . Smaller post-capillary venules and arterioles are found in the group of vessels with a size ranging between 100 and 500 mm 2 . Larger post-capillary venules and arterioles are represented by the group of vessels with a size of 500-2,000 mm 2 . Data are expressed as mean7SEM. The two-sided unpaired Student's t-test was used to analyze differences in the number of vessels per mm ear length and the average vessel size.
Computer-assisted morphometric inflammatory cell analysis CD4-, CD8-, Ly6-G-, and F4/80-labeled sections (at least six per time point) were examined using an Axiotech 100 Upright Microscope (Zeiss), and images were captured with a PowerShot G2 digital camera (Canon Deutschland GmbH). Morphometric analyses of digital images were performed using the IP-LAB software (Scanalytics). At least three individual fields per section were examined at original magnification Â 100, and the number of immunoreactive cells per mm ear length was determined as a measure of cellular infiltration. Data are expressed as mean7SEM. The two-sided unpaired Student's t-test was used to analyze differences in the inflammatory cell number.
Intravital microscopy of cutaneous blood vessels
The animal preparation and the technical and experimental aspects of the customized intravital microscopy apparatus have been described previously (von Andrian and M'Rini, 1998) . Briefly, 6 hours after challenge, 8-week-old friends virus B mice were treated with vasostatin or saline and anesthetized with a mixture of ketamine and avertin as described above. The fluorescent dye Rhodamine-6G (20 mg/kg in PBS; Sigma-Aldrich) was administered intravenously to visualize circulating leukocytes by using a VE-100 SIT Video Enhancement System (DAGE-MTI of MC Inc., Michigan City, IN). At least three superficially located post-capillary and small collecting venules in the ear skin were randomly chosen and recorded during 1-3 minutes intervals to assess the baseline rolling interactions of leukocytes. The rolling fraction was calculated as the number of rolling leukocytes multiplied by 100 divided by the total leukocyte flux as described (von Andrian and M'Rini, 1998) . Data are expressed as mean7SEM. The two-sided unpaired Student's t-test was used to analyze differences in the rolling fraction.
FACS analysis
Human dermal microvascular endothelial cells were isolated from neonatal foreskins and cultivated as described . Human dermal microvascular endothelial cells were seeded onto 10 cm dishes and starved overnight in endothelial basal media (Cambrex Bioscience, Walkersville, MD) containing 2% fetal bovine serum. Cells were washed several times with PBS and pre-treated with endothelial basal media with 0.1% BSA with or without vasostatin (at 10 or 100 mg/ml) for 1 hour at 371C before stimulation with tumor necrosis factor-a (20 ng/ml, R&D Systems, Minneapolis, MN). After 6 hours of incubation, the cells were washed with icecold PBS and detached with 1 mM EDTA in PBS. Cell-surface staining was performed with anti-human vascular cell adhesion molecule mAb (BD Pharmingen, Rockville, MD), anti-human mAb CD54/ intercellular adhesion molecule, anti-human mAb CD62e/E-selectin (both Lab Vision, Freemont, CA), anti-human mAb CD144/VEcadherin (R&D Systems, Minneapolis, MN) and corresponding isotypes (1:10 dilution) at 41C for 30 minutes in 1% fetal bovine serum in PBS. After washing, the cells were incubated with an Alexa fluor-conjugated anti-mouse mAb (1:200 dilution) for 30 minutes (Molecular Probes, Carlsbad, CA). Following a final washing step, the cells were subjected to flow cytometry analysis. Data were collected using a FACScalibur cytofluorometer (Becton Dickinson, San Jose, CA) and analyzed using CELLQuest software (Becton Dickinson).
Quantification of mRNA expression using real-time RT-PCR
Real-time RT-PCR analyses were performed in a fluorescence temperature cycler (LightCycler, Roche Applied Science, Mannheim, Germany) as described previously (Harder and Schroder, 2002) . Briefly, total RNA from inflamed and uninflamed mouse skin from both vasostatin-and saline-treated mice 24 hours after antigen challenge was extracted using Tri-reagent (Sigma-Aldrich), treated with RNase-Free DNase (Qiagen, Germany), and 2 mg of total RNA was reverse-transcribed using the First Strand cDNA Synthesis Kit for RT-PCR (Roche Applied Science). The cDNA corresponding to 50 ng of RNA served as a template in a 20 ml reaction containing 4 mM MgCl 2 , 0.5 mM each primer, and 2 ml LightCycler-FastStart DNA Master SYBR Green I mixture (Roche Applied Science).
Samples were incubated for an initial denaturing at 951C for 10 minutes, followed by 45 cycles, each cycle consisting of 951C for 15 seconds, 601C (touchdown of 11C/cycle from 66 to 601C) for 5 seconds, and 721C for 10 seconds. Cycle-to-cycle fluorescence emission readings were monitored at 721C at the end of each cycle and analyzed using LightCycler Software (Roche Applied Science). Melting curves were generated after each run to confirm amplification of specific transcripts. All quantifications were normalized to the housekeeping gene porphobilinogen deaminase. Standard curves were obtained for each primer set with serial dilutions of cDNA. Data are expressed as mean7SEM. The two-sided unpaired Student's t-test was used to analyze differences in the mRNA levels.
Primer sequences: Mouse porphobilinogen deaminase (Wang et al., 2004) 
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